'Molecular glue' redirects a cancer-driving protein to activate cell death
A two-headed molecule designed by Stanford Medicine researchers hijacks one of the most common protein drivers of B-cell lymphoma, flipping it from its role as a promoter of cell growth into an arbiter of cell death. In mice, a short course of twice-daily treatment eliminated aggressive lymphoma tumors within 11 days.
Researchers at Stanford Medicine have developed a two-headed molecular compound that can halt aggressive B-cell lymphoma tumors in mice. This innovative approach, inspired by a strategy they have been perfecting for years, involves using small molecules to physically connect a cancer-promoting protein with a molecule that activates the body's natural cell death processes.
The key player in this process is the BCL6 protein, which is often overactive in diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma. Under normal circumstances, BCL6 silences genes that would normally trigger cell death or stop cell growth, allowing cancerous cells to proliferate unchecked. The new molecule, TCIP3, works by binding to BCL6 and preventing it from silencing these death genes, while also activating the expression of these genes.
This dual action effectively flips the protein's role from promoting cell growth to triggering cell death.
To create TCIP3, the researchers employed a technique called chemically induced proximity, which allowed them to bring molecules that rarely interact under normal conditions together through chemical bonds. The resulting molecule acts like a "molecular glue," effectively locking the two interacting proteins in place and amplifying the effect.
In their experiments, TCIP3 demonstrated impressive results in mice. After just 11 days of treatment, tumors that had been implanted with human lymphoma cells disappeared completely, while control animals continued to show tumor growth. Importantly, the treated mice did not show any signs of toxicity or increased inflammation, suggesting that this new approach may have fewer side effects compared to existing treatments.
Beyond its potential for treating lymphoma, the researchers believe TCIP3 could also be used to target autoimmune diseases, which are driven by overactive germinal center cells that rely heavily on BCL6. Further research is needed to refine the molecule and test its safety and efficacy in larger animal models and eventually in human clinical trials.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
